1 Abstract 1 Although vaccines against seasonal influenza are designed to protect against circulating strains, 2 by affecting the emergence and transmission of antigenically divergent strains, they might also 3 change the rate of antigenic evolution. Vaccination might slow antigenic evolution by increasing 4 immunity, reducing the chance that even antigenically diverged strains can survive. Vaccination 5 also reduces prevalence, decreasing the supply of potentially beneficial mutations and increasing 6 the probability of stochastic extinction. But vaccination might accelerate antigenic evolution by 7 increasing the transmission advantage of more antigenically diverged strains relative to less diverged 8 strains (i.e., by positive selection). Such evolutionary effects could affect vaccination's direct benefits 9 to individuals and indirect benefits to the host population (i.e., the private and social benefits). To 10 investigate these potential impacts, we simulated the dynamics of an influenza-like pathogen with 11 seasonal vaccination. On average, more vaccination decreased the rate of viral antigenic evolution 12 and the incidence of disease. Notably, this decrease was driven partly by a vaccine-induced decline 13 in the rate of antigenic evolution. To understand how the evolutionary effects of vaccines might 14 affect their social and private benefits, we fitted linear panel models to simulated data. By slowing 15 evolution, vaccination increased the social benefit and decreased the private benefit. Thus, in 16 the long term, vaccination's potential social and private benefits may differ from current theory, 17 which omits evolutionary effects. These results suggest that conventional seasonal vaccines against 18 influenza, if protective against transmission and given to the appropriate populations, could further 19 reduce disease burden by slowing antigenic evolution. 20 2 Introduction 21
occurs by mass action, with the force of infection given by
of the time across replicate simulations. A viral population is considered too diverse when the 116 time separating two co-circulating lineages (time to most recent common ancestor, or TMRCA) 117 exceeds 10 years [38, 45] , since recent H3N2 HA lineages have coexisted for no more than 7 years.
118
The remaining 53% of simulations show qualitatively influenza-like dynamics that reproduce key 119 epidemiological and evolutionary statistics of H3N2 (Table 1) . 120 1.09 (SD = 0.14) 1.01 [40] Annual incidence per person 9.0% (SD = 1.0%) 9-15% [46] Time between infections (years, 1/annual incidence) 11.1 (SD = 1.3) 5-11 [47] [48] [49] That 47% of simulations are not H3N2-like does not necessarily imply that the model is inac- Antigenic phenotypes are represented as red points in twodimensional space (AG1 is antigenic dimension 1 and AG2 is antigenic dimension 2). The shading of the points corresponds to the time that the strains appear. Over time, new strains appear as old strains can no longer transmit to immune hosts. Viral evolution is mostly linear in antigenic space. The amount of evolution is calculated as the distance between the founding strain and the average phenotype of strains circulating at the end of the simulation. Vaccine strains (triangles) are chosen at the beginning of each year by averaging the antigenic phenotype of all circulating strains. (B) Incidence per 10 days for 20 replicate simulations. Cumulative incidence (not shown) is calculated as the sum of cases over the duration of the simulation. Although the depicted model output is without vaccination, a hypothetical vaccine distribution schedule is shown by the bars and triangles. Strain selection occurs on the first day of each year. The vaccine is then distributed beginning 300 days after strain selection for 120 days. The triangles indicate the time points of vaccine strain selection, and the matching colored bars indicate the corresponding window of vaccine distribution for the selected vaccine strain. (C) Upon contact, the risk of infection increases linearly with the distance between the infecting strain and the strain in the host's infection or vaccination history that minimizes the risk of infection (Eq. 3). In this example, for illustrative purposes, vaccines confer half the breadth of natural immunity (b = 0.5). However, by default, we simulate vaccines that have the same breadth as natural immunity (b = 1.0). (D) The sizes of antigenic mutations are chosen from a gamma distribution. The radial directions (not pictured) of mutations are chosen from a random uniform distribution.
Estimating the private and social benefits of vaccination
A linear panel regression model was fitted to simulated panel data to identify the private and social 194 benefits of vaccines over 20 years. The social benefit is also known as the "indirect effect" and the 195 private benefit is also known as the "direct effect" as defined in [54] . 196 To generate panel data, we ran simulations at six annual vaccination rates r (0%, 1%, 3%, 197 5%, 7%, and 10%) and recorded individual hosts' dates of infection and vaccination. We ran 20 198 replicates for each unique combination of rate and breadth, and randomly sampled 2,500 individuals 199 (0.005% of the entire host population) at the end of each simulation for analysis, yielding up to 2 
The fitted coefficients estimate the absolute change in the probability of infection given the 213 host population's vaccination rate and an individual's vaccination status. We converted these 214 absolute risks to odds ratios in keeping with standard reporting of influenza vaccine effectiveness.
215
For example, β 1 +β 0 1−(β 1 +β 0 ) / β 0 (1−β 0 ) gives the odds ratio of infection for an unvaccinated individual's risk 216 of infection in the current season when the population vaccination rate is 1% relative to the odds 217 of infection in an unvaccinated population. The same formula applied to β x for x ∈ {1, 2, 3, 4, 5}
218
represents the social or indirect benefits of vaccination under different vaccination policies.
219
The model is interacted (β 4 to β 30 ) to estimate the private benefit for each vaccination rate.
220
Thus, β 4 +β 0 1−(β 4 +β 0 ) / β 0 1−β 0 ) gives the ratio of the odds of becoming infected in the current season for a 221 host who has been vaccinated in the current season and is in a population with an annual vaccination 222 rate of 1% relative to the odds of infection for a host who is in a population with a 1% vaccination 223 rate but has not been vaccinated in 5 years. Likewise, β 5 +β 0 1−(β 5 +β 0 ) / β 0 (1−β 0 ) estimates the ratio of odds 224 of becoming infected in the current season given vaccination one season ago and living under a 1% 225 vaccination rate policy relative to an unvaccinated host also living under a 1% vaccination rate 226 policy. More formally, 10 k=6 β k is the impulse response to vaccination over 5 years and measures 227 the total individual-level protective benefit of vaccination over time when the vaccination rate is 228 1%. The same reasoning applies to the terms associated with the other two vaccination rates.
229
We also estimate the benefits of vaccination directly from incidence to validate the regression model. To estimate the social benefit (the indirect effect in [54]) for a specific vaccination rate r, we calculate the ratio of the odds infection for an unvaccinated host in a vaccinated population relative to the odds of infection in an unvaccinated population. For x ∈ {1, 2, 3},
To estimate the private benefit, we calculate an analogous odds ratio relative to the odds of infection for an unvaccinated host in the same vaccinated population. For y ∈ {4, ...18},
4 Results Figure 2 : High vaccination rates decrease the average amount of (A) cumulative antigenic evolution and (B) cumulative incidence. Points show mean cumulative antigenic evolution or incidence for each vaccination rate. Error bars show 95% nonparametric bootstrapped confidence intervals of the means. Densities are calculated for each vaccination rate, such that the sum of densities for each vaccination rate equals 1. Data are collected across 500 total simulations for each rate with excessively diverse simulations (TMRCA > 10 years) excluded, leaving ∼300-400 simulations per rate.
For an influenza-like pathogen, vaccination reduces the average amount of antigenic evolution 
243
Eliminating the time interval between strain selection and vaccine distribution reduces the 244 amount of antigenic evolution (Wilcoxon rank-sum test, p < 0.001) and incidence (Wilcoxon rank-245 sum test, p < 0.001) even more ( Fig. S8 ). For example, with a 300-day delay between vaccine 246 strain selection and distribution at a 5% annual vaccination rate, the virus evolves a cumulative Increasing the vaccination rate also decreases the probability that the viral population becomes 252 too diverse ( Fig. S9 ). Without vaccination, 42.5% of simulations becomes too diverse, while 253 35.6% and 3.4% become too diverse at a 1% and 5% annual vaccination rate, respectively. Thus, 254 vaccination is unlikely to increase incidence by diversifying viral populations.
255
Given the high extinction rate with vaccination, we next examined how much these reductions 256 in incidence could be attributed solely to the "ecological" effects of vaccination-the reduction in 257 prevalence and increased extinction risk from accumulating herd immunity-versus the combined 258 ecological and evolutionary impacts (Methods 3.5, Fig. S10 ). Relative to the case where the evo-259 lutionary effects of vaccines are blocked, vaccination with evolutionary effects can either increase 260 or decrease both cumulative antigenic evolution and incidence ( Fig. 3 the virus experiences some positive selection from vaccination that buffers against slowed antigenic 267 evolution. However, the strength of positive selection is not enough to overcome the factors that 268 slow evolution relative to the zero vaccination case. Such factors include increased immunity against 269 circulating strains, smaller effective viral population size reducing the probability that mutations 270 will appear, and increased probability of stochastic extinctions due to fewer infections. The trend 271 reverses above a 3% annual vaccination rate: at higher vaccination rates, the impact of vaccination 272 on antigenic evolution and prevalence is much greater. Here, the maximum absolute difference 273 occurs at a 6.5% annual vaccination rate, where the virus evolves 1.7 (95% CI 1. are needed to achieve the same average reductions in cumulative antigenic evolution and incidence 288 using broader vaccines ( Fig. S11 ). Regardless of breadth, distributing vaccines immediately after 289 strain selection (i.e., distributing more antigenically matched vaccines) helps vaccines achieve the 290 same average reductions in evolution and incidence at lower vaccination rates ( Fig. S13 ). We developed a statistical test to determine whether vaccination accelerates antigenic evolution 293 or causes excessive diversity compared to the vaccine-free case. For this test, we defined excessive 294 evolution as more than 21 antigenic units (the average amount of evolution without vaccination) 295 over the duration of the simulation, or when the TMRCA exceeded 10 years. We counted the 296 number of "excessively evolved" replicate simulations for each vaccination rate and breadth. If 297 vaccination increases the rate of evolution, the frequency of excessively evolved simulations should 298 be greater than in the vaccine-free case (Fig. S15 ).
299
We found that vaccine-driven excessive evolution only occurred at low to intermediate immune when we detected statistically significant excessive evolution, these outcomes were at most ∼ 12% 305 more common with vaccination relative to without. However, for the influenza-like parameters 306 considered, we conclude that vaccine-driven excessive evolution is rare.
Instances of excessive evolution are generally no more common with vaccination than without 308 ( Fig. S15 ). For any vaccination rate, the surviving viral populations tend to be more evolved 309 antigenically ( Fig. S11 ). Most of these viral populations would have evolved just as much without 310 vaccination, and only survive vaccination because they evolved unusually quickly. define the social benefit as one minus the ratio of the odds of infection for unvaccinated hosts in a 326 population vaccinated at a given rate relative to the odds in an unvaccinated population (Eq. 5).
327
The social benefit thus measures the relative reduction in the odds of infection due to vaccination 328 in the population. We define the private benefit as one minus the odds of infection having been 329 vaccinated relative to the risk of infection having not been vaccinated in a population vaccinated 330 at the given rate (Eq. 7). These metrics are the same as the direct effects (standardly reported as 331 vaccine effectiveness [35, 55, 56] ) and indirect effects of vaccination [54] .
332
When vaccination slows antigenic evolution, we expect that the social benefit will be greater and 333 the private benefit will be smaller than when evolutionary effects are excluded. However, although 334 the net effect of vaccination is to slow evolution, ongoing positive selection at low vaccination rates 335 provides buffers the decline in antigenic evolution, as described above (Fig. 3) At high vaccination rates (≥5%), the social benefit rises from vaccination's impact on evolution.
338
For example, when vaccination does affect antigenic evolution, at a 5% annual vaccination rate, 339 unvaccinated hosts are 84.5% (95% CI 83.5-85.5%) less likely to be infected in a vaccinated compared 340 to an unvaccinated population ( Fig. 4 , Table S3 ). When vaccination cannot affect antigenic
We found that the seasonal influenza vaccine is unlikely to accelerate evolution, assuming that the breadth of vaccine-induced immunity is similar to that of natural immunity. In simulations, 396 vaccine-driven accelerated antigenic evolution only occurs when the breadth of vaccine-induced 397 immunity is narrower than that of natural infection, and then only at low vaccination rates. The tion is sensitive to transmission rates and the distribution of mutation sizes. We chose transmission 420 and mutation parameters such that the simulated epidemiological and evolutionary dynamics match 421 those of H3N2 [38, 45] . Increasing the mutation rate, skewing the distribution of mutation sizes 422 toward large mutations, and increasing the transmission rate each increase the rate of antigenic 423 evolution and the tendency for viral populations to diversify [38, 45] such that any reduction in vaccine efficacy is caused by antigenic mismatch. In reality, antigenic 429 mismatch, poor immunogenicity, and poor blocking of transmission likely contribute to low efficacy, 430 and eradication may require more vaccination than predicted by this model.
431
We speculate that by affecting regional antigenic evolution, vaccination has the potential to 432 change influenza's phylogeography. Presently, tropical and subtropical Asia contribute dispropor-433 tionately to the evolution of H3N2 [33, 34] , which may be due to higher regional transmission [45] .
434
High vaccine coverage in seasonal populations may compound Asia's propensity to produce anti-435 genically advanced strains. Though we do not model vaccination in a metapopulation, our results 436 suggest that vaccination in Asia might have a disproportionately large impact on influenza's global 437 circulation by reducing its production of antigenically advanced strains.
438
In theory, universal vaccines that immunize against all strains necessarily slow antigenic evo-439 lution by not discriminating between antigenic variants [19] . Our results, however, suggest that 440 conventional seasonal influenza vaccines already have the potential to slow antigenic evolution and 441 eradicate seasonal influenza. Increasing seasonal vaccine immunogenicity and coverage, especially in populations that contribute substantially to influenza's evolution, could help realize similar evolutionary benefits. However, if vaccination further reduces disease burden, people may require more
[50] Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, Sagulenko P, Bedford T,
The endemic equilibrium of S eq , I eq , and R eq is
where R 0 , the basic reproductive number, is the number of secondary infections from a single 688 infected individual in a totally susceptible population.
689
The disease-free equilibrium (when
We introduce a single invading mutant I = 1 N , where N is the total population size. To 691 find the growth rate of the mutant, we develop an expression for the amount of immunity against 692 the mutant strain. The single mutant has an antigenic phenotype d antigenic units away from the 693 resident. The conversion factor between antigenic units and infection risk is notated by c. Thus, the susceptibility to the mutant is given by min{cd, 1}, and immunity to the mutant is max{1 − cd, 0}.
695
For convenience of notation, we assume cd ≤ 1. 696 We can decompose R eq into immunity conferred by recovery from natural infection R n and 697 immunity conferred by vaccination R v :
The fraction of the population immune to the invading strain is denoted R . Assuming that 699 vaccines confer a breadth of immunity relative to natural immunity b,
Note that when the mutant and resident are identical (d = 0), the immunity to the invading strain is identical to the equilibrium immunity, R = R eq . Allowing for coinfection, the fraction susceptible to the invading strain is
for large N . When the vaccination rate exceeds 1 − 1 R 0 , the resident is eradicated and S and R 701 are calculated using the disease-free equilibrium.
702
The invasion fitness s of the mutant relative to the endemic strain is the difference between the 703 per-capita growth rates. Note that since the resident is in equilibrium, dI/dt = 0.
The value of s increases with greater distance between the mutant and resident, but decreases as 705 more hosts become vaccinated (Fig. S1A) . The expected s can be used to determine the effect of Figure S1 : (A) High vaccination rates decrease the invasion fitness of mutant strains. For a given vaccination rate, the invasion fitness of a mutant increases with antigenic distance. However, the invasion fitness of a mutant at a given distance decreases as vaccine coverage increases. An example profile of invasion fitnesses is shown for d = 0.2 (the red line) in (B). Above the invasion threshold for the resident (ρ > 1 − 1/R 0 ), the mutant must be increasingly more distant to invade. The white curve shows the invasion threshold, where the invasion fitness for the mutant strain is zero. Mutants above the above the curve can invade, while mutants below the curve cannot. (C) Density of gamma-distributed mutations with a δ mean = 0.3 and δ sd = 0.6.
We decompose ∂E(s) ∂p to understand how vaccines affect selection by changing susceptibility:
≥ 0 (i.e., one cannot be more than 100% immune to infection), vaccination must 711 decrease the expected invasion fitness of the mutant, ∂E(s) ∂p ≤ 0 , slowing evolution. This decrease 712 is attributed to vaccination reducing susceptibility to the mutant by increasing immunity ( ∂S ∂R ≤ 0 713 and ∂R ∂p > 0) against any mutant. A larger breadth of vaccine-induced immunity (b) also decreases 714 the expected invasion fitness. In the main text, we show general agreement between our simulations and observations of influenza's 717 epidemiology and evolution using our parameterization. We further validate the epidemiological 718 processes of our agent-based model by removing evolution and comparing output against analytic 719 solutions to a model using deterministic ordinary differential equations. A simple analytic solution 720 to a model with antigenic evolution is intractable.
721
Classical SIR models include vaccination of newborns only. In a newborn-only vaccination 722 model, the threshold eradication rate p t = 1 − 1/R 0 ≡ γ+ν β . Here, we derive an eradication 723 threshold vaccination rate for a model where all hosts are vaccinated at the same rate.
At equilibrium:
We find agreement between the simulated equilibrium fraction susceptible and the theoretical 726 S * for a range of influenza-like values of R 0 (1.2-3.0) (Fig. S2 ). We derive a general expression for the eradication threshold first by calculating I * :
The condition for the existence of a disease-free equilibrium is I * > 0. We derive an eradication threshold p t for which I * = 0:
Since p ≥ 0, we take the nonnegative root.
Again, we find agreement between the simulated and theoretical eradication threshold vacci-732 nation rates over a range of influenza-like values of R 0 (Figs. S3, S4 ). Because we initialize the 733 simulations at the endemic equilibrium without vaccination, some damped oscillation is to be ex-734 pected, which may cause eradication at slightly lower vaccination rates than expected by theory 735 (Fig. S5 ). For instance, at R 0 = 1.8, theory predicts eradication at p = 0.0267 day −1 , while 736 simulation achieves extinction in 20/20 simulations within 20 years at p = 0.024 (Fig. S5 ).
737
The expected period of damped oscillation is derived from stability analysis. The Jacobian matrix of the SIRV model is given by
where S * and I * are the equilibrium fraction susceptible and infected, respectively. The period of oscillation (T ) is inversely proportional to the imaginary part of the dominant eigenvalue of the Jacobian matrix (Λ).
The timeseries (Fig. S5) show oscillation at annual vaccination rates of 1.3% and 1.9%. The 738 calculated periods of oscillations at these rates are 4.5 years and 8.5 years respectively, which agree with the timeseries. Since the simulation has stochastic components, the periodicity appears more 740 regular at first and becomes less predictable over time. Figure S3 : With vaccination, the simulated eradication thresholds agree with analytic predictions. The simulated threshold is the minimum vaccination rate where 40/40 simulations go extinct within 20 years. Error bars show the sampling resolution (Fig. S4 ). Simulations were initialized at the analytically derived equilibrium S, I, and R with vaccination (equation S40). There are 40 replicate simulations shown for each value of R 0 . Figure S4 : Estimation of simulated eradication thresholds without evolution, starting at the equilibrium S, I, and R with vaccination. To generate response curves, we ran 40 replicate simulations for each combination of R 0 and vaccination rate and calculated the fraction of extinct simulations. The simulated eradication threshold is the minimum vaccination rate that causes 40/40 simulations to go extinct within 20 years. When the analytic equilibrium I was nonnegative, we initialized the simulation with a single infection. Figure S5 : Simulated timeseries without evolution, starting at the endemic equilibrium without vaccination (i.e., S 0 = 1/R 0 ≡ γ+µ+p β , as in the manuscript, but in contrast to Appendix Figures 2  and 3 ). Because the population starts away from the vaccinated equilibrium, the system experiences damped oscillations, which increase the probability of stochastic extinction. Thus, we observe extinction even when the vaccination rate is slightly below the expected eradication threshold. Vaccination remains pulsed in 9-month periods, as in the model. Frequencies of susceptible (S), infected (I), recovered (R), and vaccinated (V ) individuals are shown for 20 replicate simulations. The left y-axis shows the frequencies of S (blue), R (green), and V (purple). The right y-axis shows the number of infections (red). The dashed lines shows the expected equilibrium frequencies for each class. Red points indicate extinction events. 
The host was infected this season (1) and only vaccinated 2 seasons ago. The population vaccination rate is 5% 1 2 1 0 1 0 0 1 0 1 0 Host not infected this season (1). Host vaccinated this season and 4 seasons ago.
Population vaccination rate is 5% ... The effective amount of vaccine-induced immunity in the population is calculated using the mean antigenic distance between circulating strains and the vaccinated hosts' vaccine strains. At any given time, the effective vaccine immunity is
where N is the host population size, p is the fraction of vaccinated, v i is the vaccine strain received by individual i, x is the average circulating strain, d is the antigenic distance between the strains, and c is a constant that converts between antigenic distance and risk. The horizontal line indicates the theoretical eradication threshold in an antigenically homogenous population 1 − 1/R 0 . Figure S8 : With no temporal lag between vaccine strain selection and distribution, increasing the vaccination rate quickly decreases the average amount of (A) cumulative antigenic evolution (A) and (B) incidence. Points show mean cumulative antigenic evolution or incidence for each vaccination rate. Error bars show 95% nonparametric bootstrapped confidence intervals of the mean. Data are collected from 500 total simulations for each vaccination rate with excessively diverse simulations (TMRCA > 10 years) excluded, leaving ∼300-400 simulations per rate. Unvaccinated AG1 AG2 Figure S10 : Schematic of the models where vaccination can affect antigenic evolution (dynamic, A) and where vaccination cannot affect antigenic evolution (static, B). Axes represent the principal antigenic dimensions of the 2D antigenic space. The colors of the circles represent the strain phenotypes circulating at a given time interval (the step size of the simulations is one day). The viral population starts in the lower left (purple) and evolves over time to the upper right (dark blue). The size of the circles approximates incidence. (A) In the dynamic simulations, vaccination can affect antigenic evolution. Therefore, the amount of antigenic evolution can decrease and the incidence can decrease relative to no vaccination. (B) In the static simulations, an unvaccinated population is first simulated to generate an evolutionary history that is unaffected by vaccination.
Then, in the test simulation with vaccination, the antigenic phenotypes of infections during any time interval are drawn from the unvaccinated reference simulation at the contemporaneous time interval (indicated by the arrows). Thus, the rate of antigenic evolution (the position of the viral population in antigenic space at any time) is independent of vaccination. However, incidence is determined by the epidemiological dynamics of infection and recovery, so vaccination can still affect incidence (indicated by the size of the circles).
Figure S11: Across all simulations (A&B), vaccination decreases the average (A) cumulative antigenic evolution and (B) incidence regardless of breadth. In the subset of simulations where the viral population does not go extinct (C&D), vaccines with narrow breadth are associated with greater average antigenic evolution (C) and incidence (D), but these increases are not necessarily caused by vaccination ( Fig. S14 ). Lines are colored according to the breadth of vaccine-induced immunity. Points indicate significant decrease (below the dashed line) or increase (above the dashed line) compared to no vaccination according to a Wilcoxon rank-sum test (p < 0.05) performed on at least 5 replicate simulations. Complete data are shown in Figures S12 and S15 Data are collected from 500 replicate simulations per unique combination of vaccination rate and vaccine immune breadth with excessively diverse simulations (TMRCA > 10 years) excluded, leaving ∼ 300 − 400 simulations per parameter combination. Figure S12 : Density plots of complete simulation data corresponding to Figure S11 . Points show mean cumulative antigenic evolution or incidence for each vaccination rate. Error bars show 5th and 95th percentiles for each the simulated outcomes. Data are collected from 500 replicate simulations per unique combination of vaccination rate and vaccine immune breadth with excessively diverse simulations (TMRCA > 10 years) excluded, leaving ∼ 300 − 400 simulations per parameter combination. Figure S13 : With no temporal lag between vaccine strain selection and distribution, lower vaccination rates are needed to achieve the same reductions in (A) cumulative antigenic evolution and (B) cumulative incidence compared to when vaccines are distributed 300 days after strain selection (Fig. S11 ). The solid lines show averages across all simulations, while dotted lines show averages over simulations where the viral population did not go extinct. Lines are colored according to the breadth of vaccine-induced immunity. Data are collected from 500 replicate simulations per unique combination of vaccination rate and vaccine immune breadth with excessively diverse simulations (TMRCA > 10 years) excluded, leaving ∼ 300 − 400 simulations per parameter combination. Figure S14 : Vaccination almost always reduces the rate of antigenic evolution. The subplots show the number of simulations (out of 1000 replicates for each unique combination of parameters) that demonstrate excessive evolution for each vaccination rate and breadth b. Here, excessive evolution is defined by either more than 21 antigenic units of cumulative evolution or a TMRCA > 10 years. Black lines show the number of simulations that evolve excessively without vaccination (the null expectation if vaccines do not drive faster evolution). Red bars show significantly more counts of excessive evolution compared to unvaccinated simulations (p < 0.05, Pearson's χ 2 test). Figure S17 : Average distance between the vaccine strain and the average antigenic phenotype of viruses circulating on the first day of the year (for the simulations used to calculate social and private benefits, Figs. 4, S16, Table S3 ). Distances are calculated using 20 replicate simulations for each unique vaccination rate and simulation type. Error bars show SDs. Green lines represent simulations where vaccination can affect antigenic evolution (dynamic). Orange lines represent simulations where vaccination cannot affect antigenic evolution (static).
